SAREPTA

US FDA approves expanded use of Sarepta's Duchenne gene therapy

The FDA gave accelerated approval to the therapy - the first of its kind for DMD in patients aged between four and five who can walk - in June last year. Accelerated approval is a process that allows the agency to greenlight treatments before confirmatory data shows they work.